PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2018-2023
• Biologics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Mylan
• NextSource Biotechnology
• Novartis
PART 13: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules – Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Some of the therapeutics that received orphan drug designation from the US FDA are mentioned below
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: F. Hoffmann-La Roche – Vendor overview
Exhibit 48: F. Hoffmann-La Roche – Business segments
Exhibit 49: F. Hoffmann-La Roche – Organizational developments
Exhibit 50: F. Hoffmann-La Roche – Geographic focus
Exhibit 51: F. Hoffmann-La Roche – Segment focus
Exhibit 52: F. Hoffmann-La Roche – Key offerings
Exhibit 53: F. Hoffmann-La Roche – Key customers
Exhibit 54: Merck Sharp & Dohme – Vendor overview
Exhibit 55: Merck Sharp & Dohme – Business segments
Exhibit 56: Merck Sharp & Dohme – Organizational developments
Exhibit 57: Merck Sharp & Dohme – Geographic focus
Exhibit 58: Merck Sharp & Dohme – Segment focus
Exhibit 59: Merck Sharp & Dohme – Key offerings
Exhibit 60: Merck Sharp & Dohme – Key customers
Exhibit 61: Mylan – Vendor overview
Exhibit 62: Mylan – Business segments
Exhibit 63: Mylan – Organizational developments
Exhibit 64: Mylan – Geographic focus
Exhibit 65: Mylan – Key offerings
Exhibit 66: Mylan – Key customers
Exhibit 67: NextSource Biotechnology – Vendor overview
Exhibit 68: NextSource Biotechnology – Organizational developments
Exhibit 69: NextSource Biotechnology – Key offerings
Exhibit 70: NextSource Biotechnology – Key customers
Exhibit 71: Novartis – Vendor overview
Exhibit 72: Novartis – Business segments
Exhibit 73: Novartis – Organizational developments
Exhibit 74: Novartis – Geographic focus
Exhibit 75: Novartis – Segment focus
Exhibit 76: Novartis – Key offerings
Exhibit 77: Novartis – Key customers
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations
【掲載企業】
F. Hoffmann-La Roche、Merck Sharp & Dohme、Mylan、NextSource Biotechnology、Novartis